Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group.
Kreissl S, Mueller H, Goergen H, Mayer A, Brillant C, Behringer K, Halbsguth TV, Hitz F, Soekler M, Shonukan O, Rueffer JU, Flechtner HH, Fuchs M, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Kreissl S, et al. Among authors: brillant c. Lancet Oncol. 2016 Oct;17(10):1453-1462. doi: 10.1016/S1470-2045(16)30093-6. Epub 2016 Sep 6. Lancet Oncol. 2016. PMID: 27612583
Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A, Bredenfeld H, Skripnitchenko R, Müller RP, Müller-Hermelink HK, Diehl V, Engert A; German Hodgkin Study Group. Nogová L, et al. Among authors: brillant c. J Clin Oncol. 2008 Jan 20;26(3):434-9. doi: 10.1200/JCO.2007.11.8869. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086799
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration.
Behringer K, Goergen H, Müller H, Thielen I, Brillant C, Kreissl S, Halbsguth TV, Meissner J, Greil R, Moosmann P, Shonukan O, Rueffer JU, Flechtner HH, Fuchs M, Diehl V, Engert A, Borchmann P. Behringer K, et al. Among authors: brillant c. J Clin Oncol. 2016 Dec 20;34(36):4329-4337. doi: 10.1200/JCO.2016.67.7450. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27998235
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
Nogová L, Reineke T, Eich HT, Josting A, Müller-Hermelink HK, Wingbermühle K, Brillant C, Gossmann A, Oertel J, Bollen MV, Müller RP, Diehl V, Engert A. Nogová L, et al. Among authors: brillant c. Ann Oncol. 2005 Oct;16(10):1683-7. doi: 10.1093/annonc/mdi323. Epub 2005 Aug 10. Ann Oncol. 2005. PMID: 16093276 Free article.
Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
Eich HT, Haverkamp U, Engert A, Kocher M, Skripnitchenko R, Brillant C, Sehlen S, Dühmke E, Diehl V, Müller RP. Eich HT, et al. Among authors: brillant c. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):860-5. doi: 10.1016/j.ijrobp.2005.02.053. Epub 2005 May 31. Int J Radiat Oncol Biol Phys. 2005. PMID: 15925455 Clinical Trial.
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).
Eich HT, Gossmann A, Engert A, Kriz J, Bredenfeld H, Hansemann K, Skripnitchenko R, Brillant C, Pfistner B, Staar S, Diehl V, Müller RP; German Hodgkin Study Group. Eich HT, et al. Among authors: brillant c. Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1187-92. doi: 10.1016/j.ijrobp.2007.04.035. Epub 2007 Aug 20. Int J Radiat Oncol Biol Phys. 2007. PMID: 17703895 Clinical Trial.
Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
Bauer K, Skoetz N, Monsef I, Engert A, Brillant C. Bauer K, et al. Among authors: brillant c. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD007941. doi: 10.1002/14651858.CD007941.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2017 May 25;5:CD007941. doi: 10.1002/14651858.CD007941.pub3 PMID: 21833963 Updated. Review.
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V. Engert A, et al. Among authors: brillant c. J Clin Oncol. 2007 Aug 10;25(23):3495-502. doi: 10.1200/JCO.2006.07.0482. Epub 2007 Jul 2. J Clin Oncol. 2007. PMID: 17606976 Clinical Trial.
22 results